SCHEMBL21292982

SCHEMBL21292982

Cc1nc(-c2ccc3nc(Cl)ccc3c2)cnc1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.48
▸ PIK3CD O00329 3/20 0.38
▸ PIK3CA P42336 3/20 0.38
▸ PIK3CB P42338 3/20 0.38
▸ PIK3CG P48736 3/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ HCK P08631 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ PRKDC P78527 1/20 0.38
▸ PARP1 P09874 1/20 0.37
▸ BACE1 P56817 2/20 0.36
▸ DGAT1 O75907 7/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ SOAT1 P35610 4/20 0.34
▸ NMT1 P30419 1/20 0.34
▸ IKBKB O14920 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21292970 0.78 HPGD (0.39) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL21292981 0.76 BACE1 (0.39) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL17909883 0.74 SYK (0.38) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL17909778 0.72 KDM4E (0.38) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL17909879 0.71 SRC (0.40) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL21292979 0.71 SRC (0.40) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30388731 0.70 MAPK1 (0.41) PIK3CAMTORDGAT1MAPK1IKBKB
SCHEMBL18425047 0.69 KMO (0.40) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18425042 0.69 KMO (0.39) HPGDPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL17909776 0.69 SRC (0.39) HPGDPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10981893-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2021-04-20 — — US disclosed
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2019-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981893-B2 Therapeutic inhibitory compounds SERPINB1, KLKB1, SERPINE1 HPGD 100/4885PIK3CD 1401/4885PIK3CA 1144/4885
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS SERPINB1, KLKB1, SERPINE1 HPGD 141/4885PIK3CD 1114/4885PIK3CA 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback